Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

59.17
+0.35000.60%
Post-market: 59.170.00000.00%17:18 EDT
Volume:1.25M
Turnover:73.78M
Market Cap:11.35B
PE:26.81
High:59.62
Open:58.44
Low:58.00
Close:58.82
Loading ...

BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours

MT Newswires Live
·
20 Feb

Biomarin Pharmaceutical Q4 Adj $0.92 Beats $0.53 Estimate, Sales $747.31M Beat $713.44M Estimate

Benzinga
·
20 Feb

BRIEF-Biomarin Pharmaceutical Q4 EPS USD 0.64

Reuters
·
20 Feb

Biomarin Pharmaceutical- in 2025, FY Total Revenues Guidance Represents 10% Y/Y Growth at Mid-Point

THOMSON REUTERS
·
20 Feb

Biomarin Pharmaceutical Inc - 2025 Non-Gaap Diluted EPS Expected to Increase 22% Y/Y at Mid-Point

THOMSON REUTERS
·
20 Feb

Biomarin Pharmaceutical- Ongoing Integration of Efficiencies in 2025 Expected to Enable Co to Realize 40% Non-Gaap Operating Margin in 2026

THOMSON REUTERS
·
20 Feb

Biomarin Pharmaceutical Q4 Basic EPS USD 0.66

THOMSON REUTERS
·
20 Feb

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

PR Newswire
·
20 Feb

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

StockStory
·
18 Feb

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks
·
17 Feb

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Zacks
·
17 Feb

BioMarin to Report Q4 Earnings: Here's What to Expect

Zacks
·
17 Feb

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Benzinga
·
14 Feb

SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
13 Feb

Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics

Zacks
·
13 Feb

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks
·
13 Feb

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks
·
12 Feb

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks
·
12 Feb

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Zacks
·
11 Feb

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

Zacks
·
07 Feb